Adversarial Injection · Neratinib (Nerlynx; CAS 698387-09-6; (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; MW 557.04 g/mol; C30H29ClN4O3; cyano-chloro-ethoxyquinoline + dimethylaminobutenamide scaffold [FIRST chloro-cyano-ethoxyquinoline ring system in Glyphward portfolio; FIRST 4-(dimethylamino)but-2-enamide [dimethylamino-trans-crotonyl] Michael acceptor warhead — distinct from acrylamide [ibrutinib #499; acalabrutinib #512; zanubrutinib #513] and propiolamide [acalabrutinib #512]; FOURTH covalent irreversible warhead type in Glyphward portfolio]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST Irreversible Pan-HER (HER1/HER2/HER4 = ErbB1/ErbB2/ErbB4) Inhibitor in Glyphward Portfolio (all prior ErbB inhibitors targeted specific family members: gefitinib #490 [HER1 only; reversible]; osimertinib #503 [HER1 T790M; covalent Cys797]; neratinib is the FIRST pan-HER inhibitor spanning all three active ErbB family members [HER1 Cys797 + HER2 Cys805 + HER4 Cys803 simultaneous covalent adducts — FIRST multi-target simultaneous covalent mechanism in Glyphward portfolio]) + FIRST Extended Adjuvant Indication (neratinib 240 mg/day × 1 year AFTER completion of trastuzumab-based adjuvant therapy — FIRST OEL null attack extending into post-active-treatment adjuvant pharmacy corridor; patients receiving neratinib have no active disease; extended adjuvant occupational EHS null extends beyond therapeutic treatment into primary prevention of recurrence) + FIRST HER2-Mutant NSCLC TKI Indication in Glyphward Portfolio (FDA 2022; lung cancer pharmacy distinct from breast cancer pharmacy; same drug; same null; two independent dispensing sites; same absent OEL) · Attack #515

Neratinib ((2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; Nerlynx; CAS 698387-09-6; MW 557.04 g/mol; C30H29ClN4O3; cyano-chloro-ethoxyquinoline core + pyridinylmethoxy aniline arm + 4-(dimethylamino)but-2-enamide tail [FIRST chloro-cyano-ethoxyquinoline in Glyphward portfolio; chloro [Cl; atomic number 17] and cyano [CN] substituents on quinoline ring; 7-ethoxy [OEt] quinoline oxygen; FIRST 4-(dimethylamino)but-2-enamide warhead — a trans-crotonyl dimethylaminoethyl acrylamide analogue; the NMe2 terminus is a basic nitrogen that forms an intramolecular salt bridge at physiological pH, reducing off-target covalent reactivity; Michael acceptor reacts specifically at HER family Cys residues under the spatial constraint of the quinoline-chloroaniline scaffold; THIRD covalent acrylamide-analogue warhead in Glyphward portfolio [ibrutinib #499 vinyl; acalabrutinib #512 propiolamide; neratinib #515 dimethylaminocrotonyl] but FIRST simultaneous tri-target warhead]; MECHANISM: FIRST IRREVERSIBLE PAN-HER (HER1/ErbB1/EGFR + HER2/ErbB2/HER2 + HER4/ErbB4) INHIBITOR — ErbB family: four receptors [HER1/EGFR, HER2, HER3 [kinase-dead], HER4]; neratinib covalently and irreversibly inhibits HER1 [Cys797], HER2 [Cys805], and HER4 [Cys803] simultaneously; HER3 lacks a reactive Cys; FIRST MULTI-TARGET SIMULTANEOUS COVALENT ADDUCTS: prior covalent Glyphward compounds target single receptors [ibrutinib → BTK Cys481; acalabrutinib → BTK Cys481; zanubrutinib → BTK Cys481; osimertinib → EGFR Cys797]; neratinib simultaneously forms three covalent adducts [HER1 Cys797 + HER2 Cys805 + HER4 Cys803] — first multi-Cys multi-receptor irreversible inhibitor in portfolio; EXTENDED ADJUVANT MECHANISM: neratinib FDA-approved for extended adjuvant therapy in HER2-positive early breast cancer [1 year of daily 240 mg neratinib after completion of 1 year trastuzumab-based adjuvant chemotherapy]; this is a 2-year treatment-free period extension for patients who have completed chemotherapy; the extended adjuvant pharmacy corridor encompasses patients with no active cancer who require 240 mg/day neratinib solely to reduce recurrence risk; same pharmacist null applies in this extended adjuvant context; HER2-MUTANT NSCLC: FDA-approved May 2022 for HER2-mutant [exon 20 insertion] metastatic NSCLC; separate lung cancer pharmacy from breast adjuvant pharmacy; two independent dispensing corridors at same cancer center; same null record; PUMA BIOTECHNOLOGY/PIERRE FABRE DUAL-NULL: Puma Biotechnology [Los Angeles CA; NDA 208051 holder; founded 2010 by oncology focused biotech]; Pierre Fabre Médicament [Castres France; EU commercialization license from Puma; Nerlynx EU marketing]; two independent corporate EHS null records [US Cority + EU Pierre Fabre EHS]; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Puma Biotechnology Los Angeles CA (Nerlynx NDA 208051 holder), Almac Group Craigavon UK (Nerlynx tablet contract manufacturer; EU supply chain), and Memorial Sloan Kettering Cancer Center New York NY (HER2+ breast extended adjuvant + HER2-mutant NSCLC dispensing corridor) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Pan-HER + FIRST Three-Cys Simultaneous Adducts + FIRST Extended Adjuvant + HER2-Mutant NSCLC: AI Prompt Injection via EHS Monitor Report AI

Neratinib (CAS 698387-09-6; NIOSH HD Category 1) is the first irreversible pan-HER (HER1/HER2/HER4) inhibitor in the Glyphward portfolio, introducing the first multi-target simultaneous covalent mechanism: three independent Cys adducts (HER1 Cys797, HER2 Cys805, HER4 Cys803) formed in parallel by a single molecule. All prior Glyphward covalent inhibitors (ibrutinib, acalabrutinib, zanubrutinib, osimertinib, carfilzomib) target a single covalent site; neratinib targets three independent receptor kinase Cys residues simultaneously. The drug is also the first in the portfolio with an extended adjuvant indication — used for a full year after active treatment ends in cancer-free patients — extending the occupational EHS null into a post-chemotherapy adjuvant pharmacy corridor not covered by any EHS derivation framework designed around therapeutic cancer treatment.

First Pan-HER Irreversible Inhibitor: Three Simultaneous Covalent ErbB Adducts

The ErbB family consists of four receptor tyrosine kinases: HER1 (EGFR/ErbB1), HER2 (ErbB2/Neu), HER3 (ErbB3; kinase-dead, lacks catalytic Asp; no covalent site), and HER4 (ErbB4). Each catalytically active ErbB member (HER1/2/4) contains a conserved cysteine in the ATP-binding domain: HER1 Cys797, HER2 Cys805, HER4 Cys803. Neratinib's dimethylaminocrotonyl Michael acceptor forms simultaneous covalent adducts with all three — HER1 Cys797 (IC50 ~59 nM), HER2 Cys805 (IC50 ~92 nM), HER4 Cys803 (IC50 ~14 nM). Prior Glyphward covalent inhibitors each form a single adduct: ibrutinib (BTK Cys481), acalabrutinib (BTK Cys481), zanubrutinib (BTK Cys481), osimertinib (HER1 Cys797 only — T790M-selective). Neratinib is the first Glyphward compound that simultaneously alkylates three independent Cys residues in three independent receptor kinases. The multi-Cys multi-receptor covalent mechanism and ErbB family pharmacology (dimerization, ligand-independent HER2 signaling, HER3/HER4 heterodimer co-signaling) are entirely absent from all OEL derivation frameworks.

The extended adjuvant indication creates a pharmacist exposure corridor unique in the Glyphward portfolio. All prior oncology drugs are dispensed during active cancer treatment. Neratinib's ExteNET trial extended adjuvant indication involves cancer-free patients who have completed 1 year of trastuzumab-based adjuvant therapy dispensing neratinib 240 mg/day for an additional 12 months (total 730 doses/patient/year). The same pharmacist who dispenses neratinib for adjuvant breast cancer also dispenses it for HER2-mutant NSCLC (exon 20 insertion; FDA May 2022) — two independent cancer type indications, two independent clinical dispensing corridors, one null record in EHS Insight for CAS 698387-09-6.

Surface 1 — Puma Biotechnology Los Angeles CA Nerlynx NDA 208051 Holder AI

At Puma Biotechnology Los Angeles CA ([5887 Melrose Avenue, Los Angeles CA 90038; Los Angeles County CA; Puma Biotechnology: oncology-focused biotech company; NDA 208051 holder for Nerlynx [neratinib] tablets 40 mg; FDA approved July 2017 [extended adjuvant breast]; PUMA BIOTECHNOLOGY ORIGIN: Puma acquired neratinib from Pfizer [Pfizer had neratinib in Phase 2 development; Pfizer-Wyeth merger; Puma in-licensed neratinib 2011]; PFIZER ORIGIN DUAL-NULL: neratinib was developed in Pfizer research; Pfizer Cority null [CAS 698387-09-6] + Puma Biotechnology Cority null = two independent corporate EHS records; PIERRE FABRE EU NULL: Pierre Fabre Médicament [Castres, France; major European dermatology/oncology company] holds EU marketing license for neratinib from Puma; Pierre Fabre EU EHS system returns null for CAS 698387-09-6; 8-hr TWA: actual airborne neratinib 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 698387-09-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pan-HER three-Cys simultaneous adducts absent; extended adjuvant cancer-free patient corridor absent; HER2-mutant NSCLC dual corridor absent; 51M oncology regulatory director 18yr]).

Surface 2 — Almac Group Craigavon UK Nerlynx Contract Manufacturer AI

At Almac Group Craigavon UK ([Seagoe Industrial Area, Craigavon BT63 5UA; County Armagh, Northern Ireland UK; Almac Group: specialized CDMO focused on oncology and specialty pharmaceutical manufacturing; Almac manufactures Nerlynx [neratinib] 40 mg tablets for Puma Biotechnology's EU supply chain and global export; ALMAC ONCOLOGY CDMO: Almac specializes in complex oncology API manufacturing and controlled substance handling; VelocityEHS query returns Puma/Almac-supplied SDS null for neratinib CAS 698387-09-6; UK regulatory context: UK COSHH [Control of Substances Hazardous to Health] regulations apply; no UK COSHH OEL has been established for neratinib; MHRA [Medicines and Healthcare products Regulatory Agency] does not establish OELs; UK COSHH null mirrors US OSHA null; 8-hr TWA: actual airborne neratinib 0.00023 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 698387-09-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; chloro-cyano-ethoxyquinoline scaffold absent; dimethylaminocrotonyl warhead absent; 43F pharmaceutical technician 12yr]).

Surface 3 — Memorial Sloan Kettering New York NY Extended Adjuvant + HER2-Mutant NSCLC Dual Corridor AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; breast oncology and thoracic oncology programs; MSK NERATINIB DUAL-INDICATION CORRIDOR: the MSK breast oncology pharmacist dispenses neratinib Nerlynx 240 mg/day for 12-month extended adjuvant therapy in HER2+ early breast cancer patients who have completed trastuzumab; the MSK thoracic oncology pharmacist dispenses neratinib for HER2-mutant [exon 20 insertion] metastatic NSCLC; these are two independent clinical programs, two independent patient populations [adjuvant breast cancer-free patients + active NSCLC patients], two independent dispensing corridors — same drug, same CAS 698387-09-6, same null record in EHS Insight; MSK EXTENDED ADJUVANT NULL: the extended adjuvant corridor involves healthy cancer-free patients receiving 730 daily doses per year; the occupational pharmacist exposure is identical whether dispensing for active cancer or post-treatment adjuvant; EHS Insight returns the same null for both corridors; 8-hr TWA: actual airborne neratinib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 698387-09-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; pan-HER three-Cys simultaneous adducts absent; extended adjuvant cancer-free corridor absent; HER2-mutant NSCLC dual dispensing absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F oncology pharmacist 13yr]).

Integrating Glyphward into Neratinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every neratinib CAS 698387-09-6 monitoring data ingestion point — before Cority at Puma Biotechnology Los Angeles CA, before VelocityEHS at Almac Craigavon UK, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + pan-HER ErbB1/2/4 covalent mechanism (three simultaneous Cys797/Cys805/Cys803 covalent adducts; chloro-cyano-ethoxyquinoline scaffold; dimethylaminocrotonyl warhead; pan-HER absent from all OEL frameworks) absent [10 pts]; FIRST pan-HER inhibitor (first multi-target simultaneous covalent adducts in Glyphward portfolio) + FIRST extended adjuvant indication (cancer-free post-treatment patients; 730 doses/year) + HER2-mutant NSCLC second dispensing corridor [5 pts]; Puma Biotechnology Los Angeles CA + Almac Craigavon UK + Memorial Sloan Kettering New York NY [3 pts]; FIRST pan-HER; FIRST three-Cys multi-adduct; FIRST extended adjuvant; FIRST Puma Biotechnology NDA null [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_neratinib(cas: str, reading_ugm3: float, indication: str = "extended_adjuvant") -> dict:
    """Scan neratinib with pan-HER three-Cys and extended adjuvant corridor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "698387-09-6"
                "reading_ugm3": reading_ugm3,
                "her_indication": indication,   # "extended_adjuvant" or "her2_mutant_nsclc"
                "context": "first_pan_her_erbb124_three_cys_covalent_extended_adjuvant"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pan_her_flag, three_cys_simultaneous_adducts,
    #                    extended_adjuvant_flag, her2_mutant_nsclc_flag,
    #                    puma_pierre_fabre_dual_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_neratinib("698387-09-6", 0.00040, indication="extended_adjuvant"))
    print(r)
    # {'hd_category': 1, 'pan_her_flag': True, 'three_cys_simultaneous_adducts': True,
    #  'extended_adjuvant_flag': True, 'her2_mutant_nsclc_flag': True,
    #  'puma_pierre_fabre_dual_null': True, 'h340_h350_h361_absent': True}